Tandem Diabetes Care Inc (TNDM) Stock Forecast & Price Target
Tandem Diabetes Care Inc · NASDAQ
$17.77+0.60 (+3.49%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Tandem Diabetes Care Inc, 10 rate it Buy or better, 10 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $15.50 to $55.00 (about 3.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $28.56 sits 61% above the current $17.77. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $0.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Moderate Buy
Strong Buy00%
Buy1050%
Hold1050%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Tandem Diabetes Care Inc.
As of Jul, 10 of 20 firms rate TNDM a Buy (10 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TNDM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.31 – $-0.08 · 17 analysts · -39% YoY
Next period, 17 analysts expect Tandem Diabetes Care Inc to earn $-0.19 a share (range $-0.31 – $-0.08), versus $-0.31 a year earlier. Full-year consensus is $-0.69, growing to $0.11 the year after.
REVENUE · NEXT QUARTER
$268.4M
Range $262.0M – $276.2M · 17 analysts · +8% YoY
Revenue is expected to reach $268.4M (range $262.0M – $276.2M), +7.7% year-over-year. Full-year consensus is $1.1B, rising to $1.2B next year.
Top analysts covering Tandem Diabetes Care Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNDM.
#1
Jonathan Block
Stifel · Rank #172
Hold
$22.00+23.8% to target
Overall win rate
42%
+ Follow
#2
William Plovanic
Canaccord Genuity · Rank #190
Buy
$35.00+97.0% to target
Overall win rate
36%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #317
Hold
No targeton TNDM
Overall win rate
35%
+ Follow
#4
Frank Takkinen
Lake Street · Rank #327
Buy
$50.00+181.4% to target
Overall win rate
26%
+ Follow
#5
Matt O'Brien
Piper Sandler · Rank #356
Buy
$33.00+85.7% to target
Overall win rate
25%
+ Follow
TNDM stock forecast FAQ
What is TNDM's average 12-month price target?+
The 17 analysts with a live target average $28.56 for Tandem Diabetes Care Inc over the next 12 months, ranging from a $55.00 high to a $15.50 low.
Is TNDM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 20 analyst ratings, 10 are Buy or Strong Buy, 10 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TNDM?+
The Street-high target is $55.00 (Barclays), and the Street-low is $15.50 (Deutsche Bank). The average of all 17 active targets is $28.56.
How many Wall Street analysts cover TNDM?+
20 analysts have an active rating on Tandem Diabetes Care Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering TNDM?+
Among analysts who currently cover TNDM, Jonathan Block of Stifel has the strongest overall Quantellect track record (Rank #172). Their current call is Hold with a $22.00 target.
What is Tandem Diabetes Care Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.31 – $-0.08) across 17 analysts. Full-year EPS is projected at $-0.69, rising to $0.11 the following year.
How much revenue is Tandem Diabetes Care Inc expected to report next quarter?+
Consensus revenue is $268.4M (range $262.0M – $276.2M). Full-year revenue is projected at $1.1B, growing to $1.2B next year.
Have analysts been upgrading or downgrading TNDM lately?+
As of Jul, 10 of 20 firms rate TNDM a Buy (10 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNDM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Deutsche Bank
